Medical Device Network

Brainomix expands into US territory with AI platform

Following multiple FDA clearances Brainomix grows its reach in the US with the launch of AI platform Brainomix 360.

UK based artificial intelligence (AI) company Brainomix has announced plans to conquer the US after unveiling a complete suite of US Food and Drug Administration (FDA) cleared modules within the Brainomix 360 platform for stroke care.

The Brainomix 360 platform uses AI algorithms to provide real-time readings of brain scans aiding clinicians to treat and transfer decisions for stroke patients.

According to the World Health Organization (WHO), 15 million people have strokes each year and the US Centres for Disease Control and Prevention (CDC) estimates that 691,695 people suffer from ischemic strokes each year.

Recent FDA clearances include Brainomix 360 e-CTP and Brainomix 360 e-MRI, supporting treatment decisions for thrombolysis and thrombectomy. Additionally, Brainomix introduced two new notification tools, Brainomix 360 Triage LVO and Brainomix 360 Triage ICH, providing real-time alerts to clinicians when a bleed or large vessel occlusion (LVO) is suspected.

Dr Waleed Brinjikji, Professor of Radiology and Neurosurgery at the Mayo Clinic in Rochester, Minnesota said: "We have been collaborating with the Brainomix team around numerous research projects over the past couple of years, including a recent study that validated the performance of their e-ASPECTS module.”

He added: "The results showed that the accuracy of ASPECTS scoring by physicians improved across disciplines and levels of experience, which makes the e-ASPECTS module a powerful tool for clinicians across the US who are managing stroke patients."

With an already well established presence in Europe, in August 2023 a report from the Oxford Academic Health Science Network (Oxford AHSN) showed hospitals using Brainomix 360 platform raised patient treatment rates by more than 55%. The study was conducted across 24 English hospitals and showed treatment rates went from the national average of 3.6% to 5.7% at e-Stroke hospitals.

Also in September 2023, Brainomix partnered with the TIPAL trial group to assess its e-Lung platform, an artificial intelligence-powered image processing module and tool.

More recently Switzerland based robotic firm, Nanoflex Robotics signed an agreement with Brainomix to deliver an AI-assisted magnetic navigation system for robotic surgical tools supporting stroke intervention.